TORONTO, Ontario — January 28, 2026 — Leads & Copy — NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) has closed the first tranche of its non-brokered private placement, raising gross proceeds of $3,110,000.
The First Tranche involved the issuance of 3,110,000 units at $1.00 per Unit. Each Unit includes one common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to acquire an additional common share at an exercise price of $1.35 per share for two years from the closing date.
The securities issued in connection with the First Tranche are subject to a four-month hold period expiring on May 28, 2026.
Following the closure of the First Tranche, NetraMark has 91,778,520 common shares issued and outstanding.
The company has commitments for the second and final tranche of the private placement, expected to close soon, for an additional $390,000. NetraMark plans to use the net proceeds for working capital and general corporate purposes.
Certain company insiders participated in the First Tranche, subscribing for 2,060,000 Units, constituting a “related party transaction” under Multilateral Instrument 61-101. The company is exempt from the formal valuation and minority shareholder approval requirements, as it is listed on the CSE.
NetraMark did not file a material change report at least 21 days before the First Tranche closing because the details of insider participation were not confirmed until shortly before the closing.
NetraMark focuses on developing Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions for the pharmaceutical industry. Its technology parses patient data into subsets, enabling the use of ML methods to transform data into intelligent insights. This allows NetraMark to work with smaller datasets and accurately segment diseases and classify patients for drug sensitivity and treatment efficacy.
NetraAI includes focus mechanisms that separate small datasets into explainable and unexplainable subsets. Explainable subsets derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success.
NetraMark’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously.
For more information, refer to NetraMark’s public documents on SEDAR+.
Source: NetraMark
